News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ariad Pharmaceuticals, Inc. (ARIA) Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations in KIT, an Oncogenic Driver of Gastrointestinal Stromal Tumors



4/9/2013 6:17:36 AM

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentation of preclinical data on ponatinib (Iclusig™) at the American Association for Cancer Research (AACR) Annual Meeting 2013, in Washington. The study, “Ponatinib, a pan-BCR-ABL inhibitor, potently inhibits key activating and drug-resistant KIT mutants found in GIST,” shows that ponatinib inhibits activated and mutated forms of KIT, a clinically proven oncogenic driver found in approximately 80 percent of patients with gastrointestinal stromal tumors (GIST).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES